JPWO2019191340A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019191340A5 JPWO2019191340A5 JP2020551824A JP2020551824A JPWO2019191340A5 JP WO2019191340 A5 JPWO2019191340 A5 JP WO2019191340A5 JP 2020551824 A JP2020551824 A JP 2020551824A JP 2020551824 A JP2020551824 A JP 2020551824A JP WO2019191340 A5 JPWO2019191340 A5 JP WO2019191340A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- composition
- cells
- cell immunotherapy
- cer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 65
- 210000004027 cell Anatomy 0.000 claims 35
- 238000009169 immunotherapy Methods 0.000 claims 34
- 239000000427 antigen Substances 0.000 claims 28
- 108091007433 antigens Proteins 0.000 claims 28
- 102000036639 antigens Human genes 0.000 claims 28
- 230000011664 signaling Effects 0.000 claims 28
- 210000001744 T-lymphocyte Anatomy 0.000 claims 23
- -1 CD86 Proteins 0.000 claims 21
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 18
- 230000000242 pagocytic effect Effects 0.000 claims 17
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims 14
- 206010057249 Phagocytosis Diseases 0.000 claims 13
- 108091008874 T cell receptors Proteins 0.000 claims 13
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 13
- 230000008782 phagocytosis Effects 0.000 claims 13
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims 12
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims 12
- 102000005962 receptors Human genes 0.000 claims 10
- 108020003175 receptors Proteins 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims 9
- 230000004068 intracellular signaling Effects 0.000 claims 5
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 4
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 claims 4
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 4
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 4
- 102100023123 Mucin-16 Human genes 0.000 claims 4
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims 4
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 4
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 claims 4
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 4
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 4
- 230000031146 intracellular signal transduction Effects 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 3
- 102100027207 CD27 antigen Human genes 0.000 claims 3
- 101150013553 CD40 gene Proteins 0.000 claims 3
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 3
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 3
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 3
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 3
- 101000934346 Homo sapiens T-cell surface antigen CD2 Proteins 0.000 claims 3
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 claims 3
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 claims 3
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 3
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 claims 3
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims 3
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 3
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 claims 3
- 108010031099 Mannose Receptor Proteins 0.000 claims 3
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 3
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 3
- 102100025237 T-cell surface antigen CD2 Human genes 0.000 claims 3
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 claims 3
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims 3
- 102100024324 Toll-like receptor 3 Human genes 0.000 claims 3
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 3
- 102100039357 Toll-like receptor 5 Human genes 0.000 claims 3
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims 3
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 3
- 102100033117 Toll-like receptor 9 Human genes 0.000 claims 3
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 3
- 101150098329 Tyro3 gene Proteins 0.000 claims 3
- 102100022356 Tyrosine-protein kinase Mer Human genes 0.000 claims 3
- 230000000735 allogeneic effect Effects 0.000 claims 3
- 108010018804 c-Mer Tyrosine Kinase Proteins 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 230000007969 cellular immunity Effects 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical group CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims 2
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims 2
- 102100040079 A-kinase anchor protein 4 Human genes 0.000 claims 2
- 101710109924 A-kinase anchor protein 4 Proteins 0.000 claims 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 102100026423 Adhesion G protein-coupled receptor E5 Human genes 0.000 claims 2
- 101710145634 Antigen 1 Proteins 0.000 claims 2
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims 2
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims 2
- 102100025218 B-cell differentiation antigen CD72 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 102100038078 CD276 antigen Human genes 0.000 claims 2
- 108010058905 CD44v6 antigen Proteins 0.000 claims 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 2
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 2
- 102100031507 Fc receptor-like protein 5 Human genes 0.000 claims 2
- 102000010449 Folate receptor beta Human genes 0.000 claims 2
- 108050001930 Folate receptor beta Proteins 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 2
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims 2
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 101000718243 Homo sapiens Adhesion G protein-coupled receptor E5 Proteins 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101000934359 Homo sapiens B-cell differentiation antigen CD72 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims 2
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims 2
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 2
- 101000846908 Homo sapiens Fc receptor-like protein 5 Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 2
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 claims 2
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims 2
- 101000878605 Homo sapiens Low affinity immunoglobulin epsilon Fc receptor Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 101001014223 Homo sapiens MAPK/MAK/MRK overlapping kinase Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 claims 2
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 2
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims 2
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims 2
- 101000880770 Homo sapiens Protein SSX2 Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims 2
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 2
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims 2
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 claims 2
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims 2
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 claims 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 claims 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 2
- 102100020791 Interleukin-13 receptor subunit alpha-1 Human genes 0.000 claims 2
- 101710112663 Interleukin-13 receptor subunit alpha-1 Proteins 0.000 claims 2
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims 2
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 claims 2
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims 2
- 102100038007 Low affinity immunoglobulin epsilon Fc receptor Human genes 0.000 claims 2
- 102100031520 MAPK/MAK/MRK overlapping kinase Human genes 0.000 claims 2
- 102000003735 Mesothelin Human genes 0.000 claims 2
- 108090000015 Mesothelin Proteins 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 108010008707 Mucin-1 Proteins 0.000 claims 2
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 claims 2
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 claims 2
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 2
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 102100037686 Protein SSX2 Human genes 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims 2
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 2
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims 2
- 102100035721 Syndecan-1 Human genes 0.000 claims 2
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims 2
- 102000004399 TNF receptor-associated factor 3 Human genes 0.000 claims 2
- 108090000922 TNF receptor-associated factor 3 Proteins 0.000 claims 2
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims 2
- 102100033110 Toll-like receptor 8 Human genes 0.000 claims 2
- 101150014014 Traf6 gene Proteins 0.000 claims 2
- 102100029690 Tumor necrosis factor receptor superfamily member 13C Human genes 0.000 claims 2
- 101710178300 Tumor necrosis factor receptor superfamily member 13C Proteins 0.000 claims 2
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 241000700605 Viruses Species 0.000 claims 2
- MXKCYTKUIDTFLY-ZNNSSXPHSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-beta-D-GlcpNAc-(1->3)-D-Galp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](NC(C)=O)[C@H](O[C@H]3[C@H]([C@@H](CO)OC(O)[C@@H]3O)O)O[C@@H]2CO)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O MXKCYTKUIDTFLY-ZNNSSXPHSA-N 0.000 claims 2
- CFDVGUXRLQWLJX-QGTNPELVSA-N beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-D-GlcpNAc Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)C(O)O[C@@H]1CO CFDVGUXRLQWLJX-QGTNPELVSA-N 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 102000006815 folate receptor Human genes 0.000 claims 2
- 108020005243 folate receptor Proteins 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- 230000001024 immunotherapeutic effect Effects 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 239000003550 marker Substances 0.000 claims 2
- 238000012737 microarray-based gene expression Methods 0.000 claims 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 2
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 244000045947 parasite Species 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 101150047061 tag-72 gene Proteins 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- HWFKCAFKXZFOQT-UHFFFAOYSA-N 1-(3,6-dibromocarbazol-9-yl)-3-piperazin-1-ylpropan-2-ol;dihydrochloride Chemical compound Cl.Cl.C12=CC=C(Br)C=C2C2=CC(Br)=CC=C2N1CC(O)CN1CCNCC1 HWFKCAFKXZFOQT-UHFFFAOYSA-N 0.000 claims 1
- 102100032605 Adhesion G protein-coupled receptor B1 Human genes 0.000 claims 1
- 108091023037 Aptamer Proteins 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims 1
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims 1
- 108010074708 B7-H1 Antigen Proteins 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 101001039256 Caenorhabditis elegans Low-density lipoprotein receptor-related protein Proteins 0.000 claims 1
- 101100364669 Caenorhabditis elegans lin-18 gene Proteins 0.000 claims 1
- 101100369802 Caenorhabditis elegans tim-1 gene Proteins 0.000 claims 1
- 102100025466 Carcinoembryonic antigen-related cell adhesion molecule 3 Human genes 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 102100021396 Cell surface glycoprotein CD200 receptor 1 Human genes 0.000 claims 1
- 102400001244 Cerebellin Human genes 0.000 claims 1
- 101800001299 Cerebellin Proteins 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 101100503636 Danio rerio fyna gene Proteins 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 101150018272 FYN gene Proteins 0.000 claims 1
- 102100031351 Galectin-9 Human genes 0.000 claims 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 101150046249 Havcr2 gene Proteins 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 101000694288 Homo sapiens 40S ribosomal protein SA Proteins 0.000 claims 1
- 101000796780 Homo sapiens Adhesion G protein-coupled receptor B1 Proteins 0.000 claims 1
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims 1
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims 1
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 claims 1
- 101000969553 Homo sapiens Cell surface glycoprotein CD200 receptor 1 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 1
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 1
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims 1
- 101001038037 Homo sapiens Lysophosphatidic acid receptor 5 Proteins 0.000 claims 1
- 101001030069 Homo sapiens Major vault protein Proteins 0.000 claims 1
- 101000995138 Homo sapiens NFAT activation molecule 1 Proteins 0.000 claims 1
- 101001043564 Homo sapiens Prolow-density lipoprotein receptor-related protein 1 Proteins 0.000 claims 1
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims 1
- 101000738769 Homo sapiens Receptor-type tyrosine-protein phosphatase alpha Proteins 0.000 claims 1
- 101000934341 Homo sapiens T-cell surface glycoprotein CD5 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 claims 1
- 101001103033 Homo sapiens Tyrosine-protein kinase transmembrane receptor ROR2 Proteins 0.000 claims 1
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 claims 1
- 108010043610 KIR Receptors Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 101150028321 Lck gene Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 102100040404 Lysophosphatidic acid receptor 5 Human genes 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 101100262697 Mus musculus Axl gene Proteins 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 101100364671 Mus musculus Ryk gene Proteins 0.000 claims 1
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 claims 1
- 102100034394 NFAT activation molecule 1 Human genes 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 108010029755 Notch1 Receptor Proteins 0.000 claims 1
- 108010029751 Notch2 Receptor Proteins 0.000 claims 1
- 108010029756 Notch3 Receptor Proteins 0.000 claims 1
- 108010029741 Notch4 Receptor Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- 108010071083 Patched-2 Receptor Proteins 0.000 claims 1
- 102000007497 Patched-2 Receptor Human genes 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100025244 T-cell surface glycoprotein CD5 Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 108010023649 Tripartite Motif Proteins Proteins 0.000 claims 1
- 102000011408 Tripartite Motif Proteins Human genes 0.000 claims 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 claims 1
- 102100039616 Tyrosine-protein kinase transmembrane receptor ROR2 Human genes 0.000 claims 1
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 238000011374 additional therapy Methods 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 201000000053 blastoma Diseases 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 238000013093 comparative effectiveness research Methods 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000008184 embryoma Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000005787 hematologic cancer Diseases 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 208000029824 high grade glioma Diseases 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 210000005260 human cell Anatomy 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 201000011614 malignant glioma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 210000001806 memory b lymphocyte Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000036281 parasite infection Effects 0.000 claims 1
- 238000001126 phototherapy Methods 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 150000003384 small molecules Chemical class 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Claims (37)
- （ａ）第１の標的抗原に結合する結合ドメインを含む細胞外ドメインと、
貪食シグナル伝達ドメインと、
細胞外ドメインと貪食シグナル伝達ドメインとの間に位置し、かつこれらを接続する膜貫通ドメインと
を含むキメラ貪食受容体（ＣＥＲ）を含むＣＤ４＋Ｔ細胞を含む第１の組成物、および
（ｂ）第２の標的抗原に結合する結合ドメインを含む細胞外ドメインと、
細胞内シグナル伝達ドメインと、
細胞外ドメインと細胞内シグナル伝達ドメインとの間に位置し、かつこれらを接続する膜貫通ドメインと
を含むキメラ抗原受容体（ＣＡＲ）を含むＣＤ８＋Ｔ細胞を含む第２の組成物
を含む組合せ細胞免疫療法組成物。 - （ａ）第１の標的抗原に結合する結合ドメインを含む細胞外ドメインと、
貪食シグナル伝達ドメインと、
細胞外ドメインと貪食シグナル伝達ドメインとの間に位置し、かつこれらを接続する膜貫通ドメインと
を含む第１のキメラ貪食受容体（ＣＥＲ）を含むＣＤ４＋Ｔ細胞を含む第１の組成物、および
（ｂ）第２の標的抗原に結合する結合ドメインを含む細胞外ドメインと、
貪食シグナル伝達ドメインと、
細胞外ドメインと貪食シグナル伝達ドメインとの間に位置し、かつこれらを接続する膜貫通ドメインと
を含む第２のＣＥＲを含むＣＤ８＋Ｔ細胞を含む第２の組成物
を含む組合せ細胞免疫療法組成物。 - （ａ）第１の標的抗原に結合する結合ドメインを含む細胞外ドメインと、
貪食シグナル伝達ドメインと、
細胞外ドメインと貪食シグナル伝達ドメインとの間に位置し、かつこれらを接続する膜貫通ドメインと
を含む第１のキメラ貪食受容体（ＣＥＲ）を含むＣＤ４＋Ｔ細胞を含む第１の組成物、および
（ｂ）第２の標的抗原に結合する組換えＴ細胞受容体（ＴＣＲ）を含むＣＤ８＋Ｔ細胞を含む第２の組成物
を含む組合せ細胞免疫療法組成物。 - （ａ）第１の標的抗原に結合する結合ドメインを含む細胞外ドメインと、
貪食シグナル伝達ドメインと、
細胞外ドメインと貪食シグナル伝達ドメインとの間に位置し、かつこれらを接続する膜貫通ドメインと
を含む第１のキメラ貪食受容体（ＣＥＲ）を含むＢ細胞を含む第１の組成物、および
（ｂ）第２の標的抗原に結合する結合ドメインを含む細胞外ドメインと、
細胞内シグナル伝達ドメインと、
細胞外ドメインと細胞内シグナル伝達ドメインとの間に位置し、かつこれらを接続する膜貫通ドメインと
を含むキメラ抗原受容体（ＣＡＲ）を含むＣＤ４＋Ｔ細胞を含む第２の組成物
を含む組合せ細胞免疫療法組成物。 - （ａ）第１の標的抗原に結合する結合ドメインを含む細胞外ドメインと、
貪食シグナル伝達ドメインと、
細胞外ドメインと貪食シグナル伝達ドメインとの間に位置し、かつこれらを接続する膜貫通ドメインと
を含む第１のキメラ貪食受容体（ＣＥＲ）を含むＢ細胞を含む第１の組成物、および
（ｂ）第２の標的抗原に結合する組換えＴ細胞受容体（ＴＣＲ）を含むＣＤ４＋Ｔ細胞を含む第２の組成物
を含む組合せ細胞免疫療法組成物。 - （ａ）第１の標的抗原に結合する結合ドメインを含む細胞外ドメインと、
貪食シグナル伝達ドメインと、
細胞外ドメインと貪食シグナル伝達ドメインとの間に位置し、かつこれらを接続する膜貫通ドメインと
を含む第１のキメラ貪食受容体（ＣＥＲ）を含むＢ細胞を含む第１の組成物、および
（ｂ）第２の標的抗原に結合する結合ドメインを含む細胞外ドメインと、
細胞内シグナル伝達ドメインと、
細胞外ドメインと細胞内シグナル伝達ドメインとの間に位置し、かつこれらを接続する膜貫通ドメインと
を含むキメラ抗原受容体（ＣＡＲ）を含むＣＤ８＋Ｔ細胞を含む第２の組成物
を含む組合せ細胞免疫療法組成物。 - （ａ）第１の標的抗原に結合する結合ドメインを含む細胞外ドメインと、
貪食シグナル伝達ドメインと、
細胞外ドメインと貪食シグナル伝達ドメインとの間に位置し、かつこれらを接続する膜貫通ドメインと
を含む第１のキメラ貪食受容体（ＣＥＲ）を含むＢ細胞を含む第１の組成物、および
（ｂ）第２の標的抗原に結合する組換えＴ細胞受容体（ＴＣＲ）を含むＣＤ８＋Ｔ細胞を含む第２の組成物
を含む組合せ細胞免疫療法組成物。 - （ａ）ＣＡＲの結合ドメインが、ｓｃＦｖを含み、および／または
（ｂ）ＣＡＲの細胞外ドメインが、結合ドメインと膜貫通ドメインの間にスペーサードメインをさらに含む
請求項１、４または６のいずれか一項に記載の組合せ細胞免疫療法組成物 - ＣＡＲの膜貫通ドメインが、ＣＤ２８、ＣＤ２、ＣＤ４、ＣＤ８、ＣＤ３ε、ＣＤ３δ、ＣＤ３ζ、ＣＤ２５、ＣＤ２７、ＣＤ４０、ＣＤ７９Ａ、ＣＤ７９Ｂ、ＣＤ８０、ＣＤ８６、ＣＤ９５（Ｆａｓ）、ＣＤ１３４（ＯＸ４０）、ＣＤ１３７（４－１ＢＢ）、ＣＤ１５０（ＳＬＡＭＦ１）、ＣＤ１５２（ＣＴＬＡ４）、ＣＤ２００Ｒ、ＣＤ２２３（ＬＡＧ３）、ＣＤ２７０（ＨＶＥＭ）、ＣＤ２７２（ＢＴＬＡ）、ＣＤ２７３（ＰＤ－Ｌ２）、ＣＤ２７４（ＰＤ－Ｌ１）、ＣＤ２７８（ＩＣＯＳ）、ＣＤ２７９（ＰＤ－１）、ＣＤ３００、ＣＤ３５７（ＧＩＴＲ）、Ａ２ａＲ、ＤＡＰ１０、ＦｃＲα、ＦｃＲβ、ＦｃＲγ、Ｆｙｎ、ＧＡＬ９、ＫＩＲ、Ｌｃｋ、ＬＡＴ、ＬＲＰ、ＮＫＧ２Ｄ、ＮＯＴＣＨ１、ＮＯＴＣＨ２、ＮＯＴＣＨ３、ＮＯＴＣＨ４、ＰＴＣＨ２、ＲＯＲ２、Ｒｙｋ、Ｓｌｐ７６、ＳＩＲＰα、ｐＴα、ＴＣＲα、ＴＣＲβ、ＴＩＭ３、ＴＲＩＭ、ＬＰＡ５およびＺａｐ７０膜貫通ドメイン、から選択される膜貫通ドメインを含む、請求項１、４、６、および８のいずれか一項に記載の組合せ細胞免疫療法組成物。
- ＣＡＲの細胞内シグナル伝達ドメインが、ＣＤ３ζ、ＣＤ３γ、ＣＤ３δ、ＣＤ３ε、ＣＤ５、ＣＤ２２、ＣＤ７９ａ、ＣＤ２７８（ＩＣＯＳ）、ＤＡＰ１０、ＤＡＰ１２およびＣＤ６６ｄシグナル伝達ドメインから選択されるＩＴＡＭ含有活性化シグナル伝達ドメインを含む、請求項１、４、６、８および９のいずれか一項に記載の組合せ細胞免疫療法組成物。
- ＣＡＲの細胞内シグナル伝達ドメインが、ＣＤ２７、ＣＤ２８、４－１ＢＢ、ＯＸ４０、ＣＤ３０、ＣＤ４０、ＰＤ－１、ＩＣＯＳ、リンパ球機能関連抗原－１（ＬＦＡ－１）、ＣＤ２、ＣＤ７、ＬＩＧＨＴ、ＮＫＧ２ＣおよびＢ７－Ｈ３シグナル伝達ドメインから選択される第１の共刺激性シグナル伝達ドメインを含み、
ここで、任意にはＣＡＲ細胞内シグナル伝達ドメインが、ＣＤ２７、ＣＤ２８、４－１ＢＢ、ＯＸ４０、ＣＤ３０、ＣＤ４０、ＰＤ－１、ＩＣＯＳ、リンパ球機能関連抗原－１（ＬＦＡ－１）、ＣＤ２、ＣＤ７、ＬＩＧＨＴ、ＮＫＧ２ＣおよびＢ７－Ｈ３シグナル伝達ドメインから選択される第２の共刺激性シグナル伝達ドメインを含む、請求項１、４、６および８～１０のいずれか一項に記載の組合せ細胞免疫療法組成物。 - ＣＡＲが、第１世代ＣＡＲ、第２世代ＣＡＲ、第３世代ＣＡＲまたはＴＣＲ－ＣＡＲである、請求項１、４、６および８～１１のいずれか一項に記載の組合せ細胞免疫療法組成物
- ＣＡＲの第２の標的抗原が、腫瘍抗原、ウイルス抗原または寄生生物抗原であり、
ここで、任意にはＣＡＲの第２の標的抗原が、ＣＤ１３８、ＣＤ３８、ＣＤ３３、ＣＤ１２３、ＣＤ７２、ＣＤ７９ａ、ＣＤ７９ｂ、メソテリン、ＰＳＭＡ、ＢＣＭＡ、ＲＯＲ１、ＭＵＣ－１６、Ｌ１ＣＡＭ、ＣＤ２２、ＣＤ１９、ＣＤ２０、ＣＤ２３、ＣＤ２４、ＣＤ３７、ＣＤ３０、ＣＡ１２５、ＣＤ５６、ｃ－Ｍｅｔ、ＥＧＦＲ、ＧＤ－３、ＨＰＶ Ｅ６、ＨＰＶ Ｅ７、ＭＵＣ－１、ＨＥＲ２、葉酸受容体α、ＣＤ９７、ＣＤ１７１、ＣＤ１７９ａ、ＣＤ４４ｖ６、ＷＴ１、ＶＥＧＦ－α、ＶＥＧＦＲ１、ＩＬ－１３Ｒα１、ＩＬ－１３Ｒα２、ＩＬ－１１Ｒα、ＰＳＡ、ＦｃＲＨ５、ＮＫＧ２Ｄリガンド、ＮＹ－ＥＳＯ－１、ＴＡＧ－７２、ＣＥＡ、エフリンＡ２、エフリンＢ２、ルイス式Ａ抗原、ルイス式Ｙ抗原、ＭＡＧＥ、ＭＡＧＥ－Ａ１、ＲＡＧＥ－１、葉酸受容体β、ＥＧＦＲｖｉｉｉ、ＶＥＧＦＲ－２、ＬＧＲ５、ＳＳＸ２、ＡＫＡＰ－４、ＦＬＴ３、フコシルＧＭ１、ＧＭ３、ｏ－アセチル－ＧＤ２およびＧＤ２から選択される腫瘍抗原である、
請求項１、４、６および８～１２のいずれか一項に記載の組合せ細胞免疫療法組成物。 - 組換えＴＣＲが、αβＴＣＲ、γδＴＣＲ、高親和性ＴＣＲ、可溶性ＴＣＲ、単鎖ＴＣＲまたは単一可変ドメインＴＣＲである、請求項３、５または７のいずれか一項に記載の組合せ細胞免疫療法組成物
- 組換えＴＣＲの第２の標的抗原が、ＷＴ－１、メソテリン、ＭＡＲＴ－１、ＮＹ－ＥＳＯ－１、ＭＡＧＥ－Ａ３、ＨＰＶ Ｅ７、サバイビン、αフェトプロテインまたは腫瘍新生抗原である、請求項３、５、７または１４のいずれか一項に記載の組合せ細胞免疫療法組成物。
- （ａ）ＣＥＲの結合ドメインが、ｓｃＦｖ、受容体外部ドメインまたはリガンドを含み、
および／または
（ｂ）ＣＥＲの細胞外ドメインが、結合ドメインと膜貫通ドメインの間にスペーサードメインをさらに含む、
請求項１～１５のいずれか一項に記載の組合せ細胞免疫療法組成物。 - ＣＥＲの膜貫通ドメインが、Ｔｉｍ１、Ｔｉｍ４、Ｔｉｍ３、ＦｃＲ、ＣＤ８、ＣＤ２８、ＭＥＲＴＫ、Ａｘｌ、Ｔｙｒｏ３、ＢＡＩ１、ＣＤ４、ＤＡＰ１２、ＭＲＣ１、ＦｃＲ、ＴＬＲ１、ＴＬＲ２、ＴＬＲ３、ＴＬＲ４、ＴＬＲ５、ＴＬＲ６、ＴＬＲ７、ＴＬＲ８またはＴＬＲ９膜貫通ドメインを含む、請求項１～１６のいずれか一項に記載の組合せ細胞免疫療法組成物。
- ＣＥＲの貪食シグナル伝達ドメインが、ＭＥＲＴＫ、Ｔｙｒｏ３、ＩｔｇＢ５、ＭＲＣ１、ＥＬＭＯ、Ａｘｌ、Ｓｙｋ、ＭｙＤ８８、ＦｃγＲ１、ＦｃγＲ２Ａ、ＦｃγＲ２Ｂ２、ＦｃγＲ２Ｃ、ＦｃγＲ３Ａ、ＦｃεＲ１、ＦｃαＲ１、ＢＡＦＦ－Ｒ、ＤＡＰ１２、ＮＦＡＭ１、ＣＤ７９ｂ、ＴＬＲ１、ＴＬＲ２、ＴＬＲ３、ＴＬＲ４、ＴＬＲ５、ＴＬＲ６、ＴＬＲ７、ＴＬＲ８、ＴＬＲ９、Ｔｒａｆ６、Ｔｒａｆ２またはＴｒａｆ３シグナル伝達ドメインを含む、請求項１～１７のいずれか一項に記載の組合せ細胞免疫療法組成物。
- ＣＥＲの貪食シグナル伝達ドメインが、一次貪食シグナル伝達ドメインおよび二次貪食シグナル伝達ドメインを含む、請求項１～１８のいずれか一項に記載の組合せ細胞免疫療法組成物。
- ＣＥＲの一次貪食シグナル伝達ドメインおよび二次貪食シグナル伝達ドメインが、異なる、請求項１９に記載の組成物。
- ＣＥＲの一次貪食シグナル伝達ドメインおよび二次貪食シグナル伝達ドメインが各々独立して、ＭＥＲＴＫ、Ｔｙｒｏ３、ＩｔｇＢ５、ＭＲＣ１、ＥＬＭＯ、Ａｘｌ、Ｓｙｋ、ＭｙＤ８８、ＦｃγＲ１、ＦｃγＲ２Ａ、ＦｃγＲ２Ｂ２、ＦｃγＲ２Ｃ、ＦｃγＲ３Ａ、ＦｃεＲ１、ＦｃαＲ１、ＢＡＦＦ－Ｒ、ＤＡＰ１２、ＮＦＡＭ１、ＣＤ７９ｂ、ＴＬＲ１、ＴＬＲ２、ＴＬＲ３、ＴＬＲ４、ＴＬＲ５、ＴＬＲ６、ＴＬＲ７、ＴＬＲ８、ＴＬＲ９、Ｔｒａｆ６、Ｔｒａｆ２およびＴｒａｆ３シグナル伝達ドメインから選択される、請求項１９または２０に記載の組合せ細胞免疫療法組成物。
- ＣＥＲの第１の標的抗原が、プロ貪食マーカー、腫瘍抗原、ウイルス抗原または寄生生物抗原である、請求項１～２１のいずれか一項に記載の組合せ細胞免疫療法組成物。
- 第１の標的抗原および第２の標的抗原が、同じ標的抗原または異なる標的抗原である、請求項１～２２のいずれか一項に記載の組合せ細胞免疫療法組成物。
- プロ貪食マーカーが、ホスファチジルセリンであり、
ここで、任意にはＣＥＲの結合ドメインが、ホスファチジルセリンに結合するＴｉｍ４結合ドメインを含む、
請求項２２に記載の組合せ細胞免疫療法組成物。 - ＣＥＲの第１の標的抗原が、ＣＤ１３８、ＣＤ３８、ＣＤ３３、ＣＤ１２３、ＣＤ７２、ＣＤ７９ａ、ＣＤ７９ｂ、メソテリン、ＰＳＭＡ、ＢＣＭＡ、ＲＯＲ１、ＭＵＣ－１６、Ｌ１ＣＡＭ、ＣＤ２２、ＣＤ１９、ＣＤ２０、ＣＤ２３、ＣＤ２４、ＣＤ３７、ＣＤ３０、ＣＡ１２５、ＣＤ５６、ｃ－Ｍｅｔ、ＥＧＦＲ、ＧＤ－３、ＨＰＶ Ｅ６、ＨＰＶ Ｅ７、ＭＵＣ－１、ＨＥＲ２、葉酸受容体α、ＣＤ９７、ＣＤ１７１、ＣＤ１７９ａ、ＣＤ４４ｖ６、ＷＴ１、ＶＥＧＦ－α、ＶＥＧＦＲ１、ＩＬ－１３Ｒα１、ＩＬ－１３Ｒα２、ＩＬ－１１Ｒα、ＰＳＡ、ＦｃＲＨ５、ＮＫＧ２Ｄリガンド、ＮＹ－ＥＳＯ－１、ＴＡＧ－７２、ＣＥＡ、エフリンＡ２、エフリンＢ２、ルイス式Ａ抗原、ルイス式Ｙ抗原、ＭＡＧＥ、ＭＡＧＥ－Ａ１、ＲＡＧＥ－１、葉酸受容体β、ＥＧＦＲｖｉｉｉ、ＶＥＧＦＲ－２、ＬＧＲ５、ＳＳＸ２、ＡＫＡＰ－４、ＦＬＴ３、フコシルＧＭ１、ＧＭ３、ｏ－アセチル－ＧＤ２またはＧＤ２である、請求項２２または２３に記載の組合せ細胞免疫療法組成物。
- ＣＥＲが、表１に列挙されるＣＥＲのいずれか１つである、請求項１～２５のいずれか一項に記載の組合せ細胞免疫療法組成物。
- ＣＤ４＋Ｔ細胞が、ナイーブＣＤ４＋Ｔ細胞、エフェクターメモリーＣＤ４＋Ｔ細胞またはセントラルメモリーＣＤ４＋Ｔ細胞である、請求項１～５のいずれか一項に記載の組合せ細胞免疫療法組成物。
- ＣＤ８＋Ｔ細胞が、ナイーブＣＤ８＋Ｔ細胞、エフェクターメモリーＣＤ８＋Ｔ細胞またはセントラルメモリーＣＤ８＋Ｔ細胞である、請求項１～３、６および７のいずれか一項に記載の組合せ細胞免疫療法組成物。
- Ｂ細胞が、ナイーブＢ細胞またはメモリーＢ細胞である、請求項４～７のいずれか一項に記載の組合せ細胞免疫療法組成物。
- ＣＤ４＋Ｔ細胞、ＣＤ８＋Ｔ細胞、Ｂ細胞またはそれらの任意の組合せが、ヒト細胞である、請求項１～２９のいずれか一項に記載の組合せ細胞免疫療法組成物。
- 組成物におけるＣＤ４＋Ｔ細胞のＣＤ８＋Ｔ細胞に対する比が、約１：１、１：２、１：４、１：８、１：１０または１：２０である、請求項１～３のいずれか一項に記載の組合せ細胞免疫療法組成物。
- 組成物におけるＢ細胞のＴ細胞に対する比が、約１：１、１：２、１：４、１：８、１：１０または１：２０である、請求項４～７のいずれか一項に記載の組合せ細胞免疫療法組成物。
- （ａ）第１の組成物および第２の組成物が各々、薬学的に許容される担体をさらに含み、
および／または
（ｂ）第１の組成物および第２の組成物が、同じ製剤において、または別々の製剤において存在する、
請求項１～３２のいずれか一項に記載の組合せ細胞免疫療法組成物。 - 有効量の請求項１～３３のいずれか一項に記載の組み合わせ細胞免疫療法組成物を対象に投与する事を含む、対象において疾患を治療する方法における使用のための請求項１～３３のいずれか一項に記載の組み合わせ細胞免疫療法組成物。
- 疾患が、がん、細菌感染、ウイルス感染、寄生生物感染、自己免疫疾患または神経変性疾患であり、
ここで、任意にはがんが、固形腫瘍、黒色腫、非小細胞肺がん、腎細胞癌、腎がん、血液がん、前立腺がん、去勢抵抗性前立腺がん、結腸がん、直腸がん、胃がん、食道がん、膀胱がん、頭頸部がん、甲状腺がん、乳がん、三種陰性乳がん、卵巣がん、子宮頸がん、肺がん、尿路上皮がん、膵がん、神経膠芽腫、肝細胞がん、骨髄腫、多発性骨髄腫、白血病、ホジキンリンパ腫、非ホジキンリンパ腫、骨髄異形成症候群、脳がん、ＣＮＳがんまたは悪性神経膠腫である、請求項３４に記載の使用のための組合せ細胞免疫療法組成物。 - ＣＤ４＋Ｔ細胞が対象にとって自家または同種異系であるか、ＣＤ８＋Ｔ細胞が対象にとって自家または同種異系であるか、Ｂ細胞が対象にとって自家または同種異系であるか、またはこれらの任意の組合せである、請求項３４または３５に記載の使用のための細胞免疫療法組成物。
- 組合せ細胞免疫療法組成物が、追加の治療剤と組み合わせて投与され、
ここで、任意には：
追加の治療剤が、抗体、放射線療法、化学療法剤、免疫チェックポイント分子阻害剤療法、小分子療法、細胞免疫療法、腫瘍溶解性ウイルス、電気パルス療法、ＵＶ光療法、高密度焦点式超音波療法、腫瘍溶解性ウイルス、ペプチド、ホルモン、アプタマー、抗炎症剤、抗生物質、抗真菌剤または抗ウイルス剤であり；
および／または、
第１の組成物および第２の組成物が、対象に同時に、または連続して投与され、ここで、さらに任意には第１の組成物が、第２の組成物の約１～７日後に投与される、
請求項３４～３６のいずれか一項に記載の使用のための細胞免疫療法組成物。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862649541P | 2018-03-28 | 2018-03-28 | |
| US62/649,541 | 2018-03-28 | ||
| US201862652838P | 2018-04-04 | 2018-04-04 | |
| US62/652,838 | 2018-04-04 | ||
| US201862734863P | 2018-09-21 | 2018-09-21 | |
| US62/734,863 | 2018-09-21 | ||
| PCT/US2019/024442 WO2019191340A1 (en) | 2018-03-28 | 2019-03-27 | Cellular immunotherapy compositions and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519301A JP2021519301A (ja) | 2021-08-10 |
| JPWO2019191340A5 true JPWO2019191340A5 (ja) | 2022-03-29 |
| JP7444781B2 JP7444781B2 (ja) | 2024-03-06 |
Family
ID=66240197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020551824A Active JP7444781B2 (ja) | 2018-03-28 | 2019-03-27 | 細胞免疫療法組成物およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210023135A1 (ja) |
| EP (1) | EP3774865A1 (ja) |
| JP (1) | JP7444781B2 (ja) |
| KR (1) | KR20210024443A (ja) |
| CN (1) | CN112218887A (ja) |
| AU (1) | AU2019243154A1 (ja) |
| CA (1) | CA3093973A1 (ja) |
| IL (1) | IL277584A (ja) |
| MX (1) | MX2020010241A (ja) |
| RU (1) | RU2020135107A (ja) |
| WO (1) | WO2019191340A1 (ja) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20170151281A1 (en) | 2015-02-19 | 2017-06-01 | Batu Biologics, Inc. | Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer |
| MX2019003489A (es) | 2016-09-27 | 2020-01-23 | Cero Therapeutics Inc | Moleculas del receptor de envolvimiento quimerico. |
| WO2019067328A1 (en) | 2017-09-26 | 2019-04-04 | Cero Therapeutics, Inc. | CHIMERIC ENGINEERING RECEPTOR MOLECULES AND METHODS OF USE |
| EP3876977A1 (en) | 2018-11-06 | 2021-09-15 | The Regents Of The University Of California | Chimeric antigen receptors for phagocytosis |
| US11026973B2 (en) | 2019-04-30 | 2021-06-08 | Myeloid Therapeutics, Inc. | Engineered phagocytic receptor compositions and methods of use thereof |
| WO2021046243A2 (en) | 2019-09-03 | 2021-03-11 | Myeloid Therapeutics, Inc. | Methods and compositions for genomic integration |
| WO2021067875A1 (en) | 2019-10-03 | 2021-04-08 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| US10980836B1 (en) | 2019-12-11 | 2021-04-20 | Myeloid Therapeutics, Inc. | Therapeutic cell compositions and methods of manufacturing and use thereof |
| EP4149483A2 (en) * | 2020-05-15 | 2023-03-22 | Fred Hutchinson Cancer Center | Compositions and methods for enhancing cancer immunotherapy |
| WO2022036265A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Chimeric tim receptors and uses thereof |
| WO2022036285A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Compositions and methods for treating cancer with chimeric tim receptors in combination with inhibitors of poly (adp-ribose) polymerase |
| WO2022036287A1 (en) | 2020-08-14 | 2022-02-17 | Cero Therapeutics, Inc. | Anti-cd72 chimeric receptors and uses thereof |
| EP4240367A2 (en) | 2020-11-04 | 2023-09-13 | Myeloid Therapeutics, Inc. | Engineered chimeric fusion protein compositions and methods of use thereof |
| US20240033356A1 (en) * | 2020-11-18 | 2024-02-01 | Carina Biotech Pty Ltd | Chimeric antigen receptor t cell and method |
| CN117480178A (zh) * | 2021-04-28 | 2024-01-30 | 桑昆专利有限公司 | 嵌合FC-α受体及其用途 |
| WO2023010097A1 (en) | 2021-07-28 | 2023-02-02 | Cero Therapeutics, Inc. | Chimeric tim4 receptors and uses thereof |
| CN114288399B (zh) * | 2022-01-20 | 2023-10-27 | 武汉科技大学 | 一种嵌合抗原受体联合抗肿瘤药物组合物及其应用 |
| WO2023192908A2 (en) * | 2022-03-30 | 2023-10-05 | Shoreline Biosciences, Inc. | Chimeric antigen receptors for natural killer cells and uses thereof in immunotherapy |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| NZ243082A (en) | 1991-06-28 | 1995-02-24 | Ici Plc | 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof |
| GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
| TW225528B (ja) | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
| US5747498A (en) | 1996-05-28 | 1998-05-05 | Pfizer Inc. | Alkynyl and azido-substituted 4-anilinoquinazolines |
| MX9800215A (es) | 1995-07-06 | 1998-03-31 | Novartis Ag | Pirrolopirimidas y procesos para su preparacion. |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
| GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
| CZ295468B6 (cs) | 1996-04-12 | 2005-08-17 | Warner-Lambert Company | Polycyklické sloučeniny |
| ATE308527T1 (de) | 1996-06-24 | 2005-11-15 | Pfizer | Phenylamino-substituierte triicyclische derivate zur behandlung hyperproliferativer krankheiten |
| EP0954315A2 (en) | 1996-09-13 | 1999-11-10 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
| EP0837063A1 (en) | 1996-10-17 | 1998-04-22 | Pfizer Inc. | 4-Aminoquinazoline derivatives |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| US8709412B2 (en) * | 2001-06-29 | 2014-04-29 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of TIM receptor activity in combination with cytoreductive therapy |
| JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
| WO2008042814A2 (en) | 2006-09-29 | 2008-04-10 | California Institute Of Technology | Mart-1 t cell receptors |
| CL2008002687A1 (es) | 2007-09-12 | 2009-01-16 | Genentech Inc | Uso de una combinacion farmaceutica de un compuesto derivado de tieno[3,2-d]pirimidina con un agente quimioterapeutico en el tratamiento de un trastorno hiperproliferativo; kit farmaceutico. |
| US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| US20130071414A1 (en) | 2011-04-27 | 2013-03-21 | Gianpietro Dotti | Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies |
| JP6574381B2 (ja) | 2012-08-20 | 2019-09-11 | フレッド ハッチンソン キャンサー リサーチ センター | 細胞免疫療法のための方法および組成物 |
| WO2015066262A1 (en) | 2013-11-04 | 2015-05-07 | Trustees Of Dartmouth College | Methods for preventing toxicity of adoptive cell therapy |
| JP6640726B2 (ja) * | 2014-02-14 | 2020-02-05 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | キメラ抗原受容体及びその製造方法 |
| CN113150112B (zh) | 2014-05-29 | 2024-02-06 | 美国卫生和人力服务部 | 抗人乳头瘤病毒16 e7的t细胞受体 |
| US20170209492A1 (en) * | 2014-07-31 | 2017-07-27 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| WO2016187349A1 (en) | 2015-05-18 | 2016-11-24 | Tcr2, Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| CN115747168A (zh) * | 2015-07-28 | 2023-03-07 | 宾夕法尼亚大学董事会 | 表达嵌合抗原受体的修饰单核细胞/巨噬细胞及其用途 |
| US10934331B2 (en) * | 2016-08-12 | 2021-03-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for enhancing immune responsiveness in an individual toward a target cancer cell population comprising apoptotic cells |
| MX2019003489A (es) * | 2016-09-27 | 2020-01-23 | Cero Therapeutics Inc | Moleculas del receptor de envolvimiento quimerico. |
| WO2019067328A1 (en) * | 2017-09-26 | 2019-04-04 | Cero Therapeutics, Inc. | CHIMERIC ENGINEERING RECEPTOR MOLECULES AND METHODS OF USE |
-
2019
- 2019-03-27 US US17/040,472 patent/US20210023135A1/en active Pending
- 2019-03-27 CN CN201980036210.7A patent/CN112218887A/zh active Pending
- 2019-03-27 EP EP19718875.8A patent/EP3774865A1/en active Pending
- 2019-03-27 AU AU2019243154A patent/AU2019243154A1/en not_active Abandoned
- 2019-03-27 WO PCT/US2019/024442 patent/WO2019191340A1/en unknown
- 2019-03-27 CA CA3093973A patent/CA3093973A1/en active Pending
- 2019-03-27 MX MX2020010241A patent/MX2020010241A/es unknown
- 2019-03-27 JP JP2020551824A patent/JP7444781B2/ja active Active
- 2019-03-27 RU RU2020135107A patent/RU2020135107A/ru unknown
- 2019-03-27 KR KR1020207030662A patent/KR20210024443A/ko unknown
-
2020
- 2020-09-24 IL IL277584A patent/IL277584A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2020135107A (ru) | Клеточные иммунотерапевтические композиции и их применения | |
| RU2020135106A (ru) | Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения | |
| JPWO2019191340A5 (ja) | ||
| JP2018521628A5 (ja) | ||
| US20200255541A1 (en) | Compositions and methods for treatment of cancer | |
| JP2022113880A5 (ja) | ||
| JP2017531687A5 (ja) | ||
| RU2016121174A (ru) | МОДИФИЦИРОВАННЫЕ ГЕМОПОЭТИЧЕСКИЕ СТВОЛОВЫЕ КЛЕТКИ/КЛЕТКИ-ПРЕДШЕСТВЕННИКИ И Не-Т ЭФФЕКТОРНЫЕ КЛЕТКИ, И ИХ ПРИМЕНЕНИЕ | |
| JP2020511136A5 (ja) | ||
| JP2017500009A5 (ja) | ||
| JPWO2019191339A5 (ja) | ||
| Roda-Navarro et al. | Understanding the spatial topology of artificial immunological synapses assembled in T cell-redirecting strategies: a major issue in cancer immunotherapy | |
| US11976121B2 (en) | CD123-binding chimeric antigen receptors | |
| RU2017114174A (ru) | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии | |
| RU2016129045A (ru) | Меченые химерные эффекторные молекулы и их рецепторы | |
| JP2015527070A5 (ja) | ||
| JP2017501702A5 (ja) | ||
| Urbanska et al. | Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells | |
| WO2012079000A4 (en) | Use of chimeric antigen receptor-modified t cells to treat cancer | |
| WO2018156802A1 (en) | Compositions and methods for treatment of cancer | |
| JP2021500859A (ja) | Ｎｆｋｂシグナル伝達の増強を伴うキメラ抗原受容体 | |
| US20230121135A1 (en) | Compositions and methods for targeting cd33-expressing cancers | |
| US20200129554A1 (en) | Chimeric antigen receptors with mutated cd28 costimulatory domains | |
| JP2023548844A (ja) | Ｃｄ７を標的にするキメラ抗原受容体及びその使用 | |
| US20210024608A1 (en) | Nkg2d chimeric antigen receptors |